Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.IMMUNE Pharmaceutical has selected Lonza to produce its experimental drug Bertilimumab as a treatment for various inflammatory disorders.
Subscribe to our email newsletter
Under the agreement, Lonza is responsible to produce materials for Phase 2 trial at its mammalian development and manufacturing plant.
IMMUNE claims its human immunoglobulin monoclonal antibody Bertilimumab is useful for eosinophilic inflammatory bowel diseases (IBD) -Crohn’s disease and ulcerative colitis- and eosinophilic gastro-intestinal diseases (EGID).
IMMUNE CEO Daniel Teper said the company strengthened its internal bio-manufacturing expertise by appointing David Naveh, former chief technical officer of Bayer Biologics Worldwide, to its board of directors.